Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis-Reference-Cited by-同舟云学术

Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis

Published:2022-11-29 Issue:4 Volume:28 Page:380-388
ISSN:1323-7799
Container-title:Respirology
language:en
Short-container-title:Respirology

Author:

Tanahashi Hiroki¹,Yamaguchi Kakuhiro¹^ORCID,Kurose Koji²,Nakao Satoshi³,Sakamoto Shinjiro¹,Horimasu Yasushi¹^ORCID,Masuda Takeshi¹^ORCID,Miyamoto Shintaro¹,Nakashima Taku¹^ORCID,Iwamoto Hiroshi¹^ORCID,Fujitaka Kazunori¹,Hamada Hironobu⁴,Oga Toru²,Oka Mikio⁵,Hattori Noboru¹

Affiliation:

1. Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

2. Department of Respiratory Medicine Kawasaki Medical School Okayama Japan

3. Department of Internal medicine Mitsugi General Hospital Hiroshima Japan

4. Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

5. Department of Immuno‐Oncology Kawasaki Medical School Okayama Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14425

Reference29 articles.

1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy

3. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer

4. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors

5. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer